Neo Ivy Capital Management Invests $598,000 in Edwards Lifesciences Corporation $EW

Neo Ivy Capital Management bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 7,684 shares of the medical research company’s stock, valued at approximately $598,000.

A number of other large investors have also recently bought and sold shares of the company. True Wealth Design LLC increased its holdings in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. Hantz Financial Services Inc. lifted its stake in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $30,000. Finally, Strengthening Families & Communities LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $34,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,144 shares of company stock worth $6,685,688 in the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $81.71 on Monday. The company has a market capitalization of $47.46 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The company’s fifty day moving average price is $82.56 and its 200 day moving average price is $81.47. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.